search
FDA
Trends
- 1CDC and FDA link E. coli outbreak to raw milk cheese brandโE. coli outbreak linked to raw milk cheese brand: CDC, FDA
Federal health agencies have connected an E. coli outbreak to a raw milk cheese brand, according to the CDC and FDA. The announcement has put a spotlight on the risks of unpasteurized dairy products, with news outlets including ABC News and KAKE reporting the link. Consumers are being urged to check whether products they have purchased are affected.
- 2Cyclosporiasis outbreak 'not fully under control,' ex-FDA chief warnsโผCyclosporiasis outbreak not 'fully under control,' former FDA chief says
A former FDA commissioner has warned that the ongoing cyclosporiasis outbreak in the United States is not fully under control, contradicting any suggestions that the foodborne intestinal illness has been contained. Cyclospora infections, typically linked to contaminated produce, cause prolonged diarrhea and fatigue. The warning is drawing attention to the scale of the outbreak and the adequacy of the response from health authorities.
- 3
The FDA has announced a recall of raw milk cheese linked to an E. coli outbreak. The recall notice is being widely carried by local news outlets across the United States. Consumers who purchased the product are advised to check for affected batches, and health officials are warning about the risks of eating cheese made from unpasteurized milk during the ongoing outbreak investigation.
- 4
The FDA has announced a new nationwide recall of a blood pressure medication, prompting the agency to urge patients taking the affected product to check their supply and consult their doctor or pharmacist. Further details, including the manufacturer, specific lot numbers, and the reason for the recall, have not been reported.
- 5Disc Medicine Faces FDA Setback And Legal InvestigationsโIs Disc Medicine (IRON) Cheap On FDA Setback And Legal Investigations?
Disc Medicine (IRON) is under scrutiny following an FDA setback and the disclosure of legal investigations, prompting investors to question whether the biotech stock is now undervalued. Coverage focuses on whether the share price already reflects the regulatory disappointment and litigation risks, or whether further downside remains for shareholders.